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Abstract 
 
The tumour suppressor TP53 is one of the most frequently mutated genes in human cancers. The 
majority of these mutations, located into the DNA binding domain, results in the production of mutated 
proteins that lose the wild-type functionality but can acquire new oncogenic functions (gain-of-function, 
GOF). We previously showed that p53R273H mutation promotes tumour growth, stromal invasion and 
angiogenesis in xenografted HT-29, suggesting a role of mutant p53 in the modulation of the tumour 
microenvironment (TME). In the first part of the study it has been explored whether p53 mutants might 
have role in modulating cytokines/secretory factors production. Cytokines profile analyses on 
conditioned media derived from a panel of human cancer cell lines showed that endogenous mutant 
p53 depletion increases significantly the secreted form of IL-1Ra (sIL-1Ra). The sIL-1Ra is a naturally 
occurring anti-inflammatory cytokine that acts as a specific antagonist of IL-1β. Confirmatory analyses  
showed that mutant p53 represses sIL-1Ra at transcriptional level, identifying by ChIP assays specific sIL-
1Ra regulatory regions required for mutant p53 physical recruitment. Moreover, further studies 
identified the transcriptional co-factor MafF as a required player to recruit by protein-protein 
interaction mutant p53 on the sIL-1Ra promoter. Indeed, we showed that MafF endogenous depletion 
(RNAi) impairs mutant p53 recruitment on the sIL-1Ra promoter restoring its activity. Functional studies 
showed that mutant p53 contributes to maintain a prone inflammatory response by sIL-1Ra down-
regulation. Indeed, either mutant p53 depletion or recombinant sIL-1Ra (Kineret) delivery impairs IL-1b 
response in vitro and in vivo. Taken together, these results reveal a novel oncogenic mutant p53 GOF 
activity, exerted by the repression of sIL-1Ra that contributes to generate a pro-inflammatory tumour 
microenvironment promoting tumour malignancy. The second part of the study has been dedicated to 
the identification and characterization of a more physiological experimental model, as 
immunocompetent mice, to better study mutant p53/TME crosstalk. The analysis of chemically induced 
mammary tumours in p53+/R172H, p53R172H/R172H  and p53+/+  genetically engineered mutant p53R172H 
knock-in mice, showed that mutant p53 occurrence strongly impacts on tumour onset, tumour 
differentiation and increases the recruitment of macrophages into the tumour milieu. Finally, in order to 
identify a feasible, less expensive and more reliable system than the genetically engineered mouse, we 
focused on the generation and initial characterization of a syngeneic  orthotopic model of breast cancer 
in immunocompetent mice, by using a breast cancer cell line, named 44-1, derived from a p53R172H/R172H 
chemically induced mammary tumour. This model will be useful to confirm the whole data obtained and 
to examine in depth the fine regulation exerted by mutant p53 on the  tumour microenvironment. 
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Chapter 1        
Introduction 
 
Wild-Type and Mutant p53 
 
p53 structure 
 
The human TP53 gene resides on chromosome 17p13.11-3 and encodes one of the most 
intensively studied oncosuppressors, the p53 protein. The genomic organization of TP53 
exhibits a high degree of similarity among different species. Eleven exons are interrupted by 10 
introns. Exon 1 of TP53 is a non-coding exon, whereas exons 2–11 code for the 393-amino-acid 
protein. Exons 5–8 are regions  highly conserved through evolution.4   
p53 protein is composed of several structural and functional domains (Figure1): a N-terminus 
region containing a transactivation domain (residues 1-42) and a proline-rich region (residues 
61-94), a central core containing the DNA binding domain (residues 102-292), and a C-terminal 
region (residues 301-393) containing an oligomerization domain (residues 324-355), a strongly 
basic regulatory domain (residues 363-393), a nuclear localization signal (NLS) and a nuclear 
export signal (NES).5 
 
Figure 1. p53 protein structure. Modified from Bai et al. 2006 
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The N-terminal domain of p53 is required to activate transcription and to regulate p53 function 
and stability by interacting respectively with transcription factors (such as p300 and CBP), and 
Mdm2, an E3 ubiquitin ligase that targets p53 for degradation in the proteasome.6-9 The DNA-
binding domain is required for sequence-specific DNA binding (the consensus sequence 
contains two copies of the 10-bp motif 5’-PuPuPuC(A/T)-(T/A)GPyPyPy-3’, separated by 0-13 
bp).10,11 The oligomerization domain (residues 324–355) allows p53 dimerization and 
tetramerization.12-14 The basic C-terminus of p53 (residues 361–393) is a negative regulatory 
domain that is believed to modulate sequence-specific DNA binding.15,16 According to the 
allosteric/conformational model, the C-terminus controls whether p53 exists in a “latent” or 
“active” conformation for high-affinity DNA binding. The basic C-terminus could force p53 into 
a non-DNA-binding “latent” conformation by interacting with the core or other domains of the 
protein.17 Post-translational modification (phosphorylation/acetylation) of the C-terminus 
following cellular stress could convert p53 into an “active” conformation,  inducing an 
enhanced transcriptional activity.17,18 The C-terminus has also been implicated in induction of 
cell death.19 
p53 functions 
Under non-stress condition, p53 is a short-lived nuclear protein with a half-life of ∼5–20 min in 
most cell types The Mouse double minute 2 homolog (MDM2), an E3 ubiquitin-protein ligase ,is 
the most critical negative regulator for p53.20,21  
p53 can be activated by a wide variety of stress signals, including DNA damage, hypoxia, and 
oncogene activation.15 Following activation, p53 normally functions as a sequence-specific 
transcription factor binding to p53 responsive elements on target genes regulatory regions as a 
homotetramer,22 and plays important roles in cell cycle control, senescence,  apoptotosis,15,23,24 
and metabolism25 in order to suppress cancer. A large number of genes have been shown to be 
transcriptional targets of p53. The p53 pathway utilizes G1/S and G2/M checkpoint mechanisms 
to arrest cell-cycle progression, thus preventing propagation of DNA damage while cells 
attempt to repair it. It is well-established that p53 can induce G1 arrest through transcriptional 
induction of p21, a cyclin-dependent kinase inhibitor.26,27 p53 was also reported to 
transcriptionally activate GADD45 (growth arrest and DNA-Damage inducible 45) and 14-3-3s 
(tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, sigma 
polypeptide), which in turn leads to G2 arrest.28,29 However, if the damage is too severe, 
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activation of the p53 pathway results in apoptotic cell death to avoid the division of cells with 
unrepaired DNA and possible malignant transformation.19,30 To this aim, p53 induces expression 
of a set of target genes involved in apoptosis, PUMA (p53 up-regulated modulator of 
apoptosis), Bax (BCL2-associated X protein), Noxa (PMAIP1), PIG3 (tumour protein p53 
inducible protein 3), Killer/DR5 (tumour necrosis factor receptor superfamily, member 10b), Fas 
(Fas cell surface death receptor), Perp (p53 apoptosis effector related to PMP-22), and p53AIP1 
(tumour protein p53 regulated apoptosis inducing protein 1).24 Recent studies have shown that 
p53 can also regulate apoptosis through a transcription-independent pathway. In response to 
stress, a fraction of the p53 protein translocates to mitochondria, where p53 interacts with 
anti-apoptotic Bcl-xL and Bcl-2 to inhibit their functions, resulting in the release of cytochrome 
c from the mitochondria and thereby induces apoptosis.31,32  
Another important function of p53 is the induction of senescence. Many DNA-damaging agents 
used in chemotherapy can activate p53 and induce senescence. Many senescence signals 
activate p53, which in turn transactivates p21 and induces p53-dependent senescence.33-36 
However, the mechanism by which p53 induces senescence is not as clear as the mechanisms 
for apoptosis and cell cycle arrest.  
An important feature of p53 is its involvement in the autophagy regulation.37 p53 has been 
reported to promote autophagy through different mechanisms, which may contribute to the 
role of p53 in tumour prevention. p53 promotes autophagy through inhibition of the mTOR 
(mammalian target of rapamycin) pathway, which is a critical negative regulator of 
autophagy.38 p53 also induces the expression of several genes, including DRAM (DNA-damage 
regulated autophagy modulator 1), PUMA, ISG20L1 (interferon-stimulated exonuclease gene 20 
kDa-like 1), and Ei24 (etoposideinduced 2.4), to promote autophagy.39-41 
In addition to transcriptional regulation of protein-coding genes, recent studies have shown 
that p53 can transcriptionally regulate the expression of miRNAs as a new mechanism of p53 
tumour suppressive functions.42,43 p53 regulates the expression of miR34-a/b/c through direct 
binding to the p53-responsive elements in their promoters. miR-34 family members repress the 
expression of several targets genes involved in the regulation of cell cycle, cell proliferation, and 
survival, including cyclin E2, CDK4/6, and BCL2. Ectopic expression of miR-34 family members 
promotes p53-mediated apoptosis, cell cycle arrest, and senescence.44-46 Since then, a group of 
miRNAs has been reported to be directly induced by p53 oncosuppressive functions (miR-145, 
miR-107, miR-192/194/215, miR-15a/16-1, miR-215, and let-7).42,43 In addition to the 
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transcriptional regulation p53 promotes the post-transcriptional maturation of specific miRNAs 
(miR-16-1, miR-143, miR-145),47 and affects the miRNA target selection by regulating RNA-
binding proteins, such as RBM38 (RNA-binding motif protein 38), which competes with miRNAs 
for binding to 30-UTRs of mRNAs of target genes.48 
p53 Mutations 
More than 30,000 somatic mutation data of p53 appear in the international agency for research 
on cancer (IARC) TP53 database version R17 (http://www-p53.iarc.fr/).49 
The frequencies of reported TP53 mutations vary considerably between cancer types, ranging 
from ~10%  in haematopoietic malignancies  to 50–70%  in ovarian, colorectal and head and 
neck cancers.50  Alterations have been found in virtually every region of the protein.51 The 
majority of this p53 alterations result in missense point mutations, leading to the substitution 
of a single amino acid residue. These substitutions occur throughout the p53 protein, but most 
commonly cluster within the DNA binding domain, with six ‘‘hotspot’’ amino acids that are 
most frequently substituted (R175, G245, R248, R249, R273 and R282).52 The mutations in the 
structured core of p53 can have significant consequences to p53 protein folding. Indeed the 
mutations have been divided into two categories: structural mutants (such as R175H) that can 
cause unfolding of the p53 protein, and DNA-contact mutants (such as R273H) that change 
amino acids critical for DNA binding.53 These mutations abrogate the TP53 tumour suppressor 
functions, reducing the ability of the cell to induce a proper p53 response; if both alleles are 
mutated, or if the remaining allele is lost (loss of heterozygosity), the cells will be totally 
deprived of anticancer protection by p53. Furthermore, many mutant (mut) p53 isoforms can 
exert dominant–negative effects over co-expressed wtp53, by forming mixed tetramers that 
are incapable of DNA binding and transactivation. Hence, through such mechanism , the cell 
may be rendered totally deficient of wtp53 function, in particular if the mutant protein is 
expressed at higher level.54 
It is becoming clear that at least some of these mutp53 proteins give rise to a more aggressive 
tumour profile, indicating that they have acquired novel functions, different from the wild type 
(wt) oncosuppressive functions. 
Gain-of-function of mutant p53 
The concept of mutp53 gain-of-function (GOF) was first suggested 20 years ago, when the 
introduction of mutp53 into p53-null cells was shown to increase their ability to form colonies 
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in soft agar in vitro and tumours in mice.55 Since then, numerous publications have 
demonstrated many mutp53 GOFs in a large number of cell lines with a variety of p53 
mutations.56 The GOF hypothesis has recently been reinforced by in vivo experiments showing 
that mice expressing mutp53 have a more aggressive and metastatic tumour profile than p53-
null or p53 wild-type mice.57-60 During these years, different models for mutp53 GOF have been 
proposed.61  
Model 1: Mutant p53 binds directly to target genes DNA to alter their expression. 
Since mutp53 proteins retain the N-terminal transcriptional transactivation domain, much of 
their activity have been related to a direct ability to regulate target gene expression. The amino 
acid substitutions within the DNA-binding domain may change sequence-specific DNA binding 
raising the possibility that some mutp53 proteins may recognize a specific mutp53 response 
element, allowing them to act as an oncogenic transcription factor. However, a mutp53-specific 
consensus sequence has not been identified yet. It has been demonstrated that mutp53 
directly interacts with other parts of the DNA, including sequences matrix attachment regions62 
or G/C-rich DNA around transcription start sites (TSS) of target genes63 and  providing other 
mechanisms to directly regulate gene expression. 
Model 2 : Mutant p53 binds  transcription factors to enhance or prevent their function. 
The best-described transcriptional function of mutp53 is its ability to interact with other 
transcription factors and modulate the expression of their target genes. In some cases, mutp53 
increases the activity of the transcription factor partner, whereas in other cases inhibits its 
activity. Following exposure to low levels of DNA damage, the DNA topoisomerase 2-binding 
protein 1 (TopBP1) recruits mutp53 and the transcriptional cofactor p300 to target gene pro-
moters. PLK2 kinase can phosphorylate mutp53 and stimulate the binding of mutp53 to p300. 
The phosphorylated mutp53–p300 complex subsequently interacts with NF-Y to induce 
transcription of a number of genes controlling different phases of the cell cycle.64-66 Mutp53 
complexes with the KLF17 transcription factor and decreases the metastatic suppressor 
function of KLF17 in breast cancer cell lines by reducing its recruitment on EMT target gene 
promoters.67 In response to TGF-β treatment, SMAD2 promotes the mutp53--p63 complex, 
leading to the inhibition of p63-driven gene expression.68 It has been recently demonstrated 
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that certain mutp53 proteins are able to form prion-like aggregates,69 which may contribute to 
the binding and inhibition of p53 family members.70 
Model 3 : Mutant p53 interacts with proteins changing their function directly. 
Mutp53 is also known to bind and modulate the function of proteins that are not directly 
involved in the transcription process. Recent data showed mutp53 binds and inhibits the 
tumour suppressor DAB2IP in the cytoplasm of cancer cell lines, promoting tumour progression. 
Indeed, interfering mutp53-DAB2IP interaction reduces aggressiveness of xenografted cancer 
cells.71 By interacting with MRE11, a DNA nuclease involved in DNA repair, mutp53 prevents the 
MRN (MRE11–RAD50–NSB1) complex to phosphorylate and activate Ataxia Telangiectasia 
Mutated protein (ATM), the primary double strand break sensor, inhibiting the DNA double-
strand breaks processing.72,73 The structural mutp53 proteins have been demonstrated to 
induce H-Ras activity by binding and suppressing the activity of the cell cycle regulator BTG2, 
and preventing it from repressing H-Ras.74  
Mutant p53 GOF in genomic instability 
Genomic instability is defined as an increased  rate of DNA alterations. One of the first link 
between mutp53 and genomic instability was shown in 1998 by Gualberto et al, who clearly 
demonstrated that human mutp53 can disrupt normal spindle checkpoint control, leading to 
accumulation of cells with polyploidy genomes.75 Ectopic expression of murine p53 R172H 
mutation (the equivalent of human R175H mutation) in p53-null primary mouse mammary 
epithelial cells results in aberrant centrosome amplification, multipolar mitoses, and 
consequently increased numbers of chromosomes76. In vitro data also suggest that mutp53 can 
facilitate structural chromosomal abnormalities by interacting with and inhibiting proteins 
involved in DNA repair. MRE11 sequestered by mutp53 proteins limit ATM phosphorylation and 
activation resulting in bypassing the G2/M DNA damage checkpoint.77 Recently, it has been 
demonstrated that mutp53 forms a transcriptional repressive complex with E2F4 protein onto 
the regulatory regions of BRCA1 and RAD17 genes inhibiting their expression. BRCA1 and 
RAD17 play a pivotal role in DNA damage repair.78 
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Mutant p53 GOF in cell death and drug resistance 
One distinctive characteristic of many p53 GOF mutants is the ability to confer an elevated 
resistance to a variety of pro-apoptotic signals, such as serum starvation,79 γ-irradiation and 
chemotherapy treatment (e.g. doxorubicin and cisplatin),80 12-O-tetradecanoylphorbol 13-
acetate,81 TNFα82 and vitamins.83 Recently it has been suggested that mutp53P151S displays 
Anoikis resistance,84 which is essential for survival of metastatic cells.85 Several mechanisms can 
be attributed to mutp53-dependent death resistance. For instance mutp53 was found to 
transcriptionally induce the expression of the multidrug resistance gene MDR1 by stimulating 
its promoter. MDR1 is an adenosine triphosphate-dependent efflux pump that transports 
foreign substances out of cells and clears drug accumulation in cells.86 Furthermore, mutp53 
was found to modulate the expression of genes directly involved in cell death regulation by 
inducing the expression of the antiapoptotic Bcl-xL,87 EGR1,88 and repressing the proapoptotic 
gene Fas.89 
Mutant p53 GOF in Cell Migration and Invasion 
Advanced stages in tumour progression are characterized by acquisition of  cancer cells ability 
to invade adjacent tissue, migrate toward distant sites, and seed metastases. Recently, it has 
been demonstrated that mutp53 enhances EMT in prostate tumour cells by elevating the 
expression of Twist1, a key regulator of EMT.90 This is further supported by another recent 
study suggesting that mutp53 enhances EMT by modulating the miR-130b–Zeb1 (zinc finger E-
box binding homeobox 1) axis in endometrial cancer.91 An important role of mutp53 in the 
regulation of EMT has been demonstrated also in invasive breast carcinoma. Mutp53 is able to 
induce cell-motility by suppressing KLF17, a transcription factor which reduces cell migration 
and invasion by decreasing CD44, PAI-1 and Cyclin-D1 expressions.67 Furthermore, recent data 
show that mutp53 upregulate the expression of myosin-X, a protein that transports integrins to 
the filopodia tips and thus regulates filopodia stability. Myosin-X is frequently highly expressed 
in breast cancers and mediates adhesion, migration, invasion, and metastasis of breast cancer 
cells in vitro and in vivo.92 
Mutant p53 GOF in cell proliferation 
When p53 is mutated the wild type functions leading to cell cycle arrest or cell death following 
various types of stress are compromised, leading to enhanced cell proliferation, one of the 
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typical hallmarks of cancer cells. Moreover, mutp53 has been demonstrated to upregulate or 
downregulate target genes involved in the regulation of cell cycle. Mutp53 interacts with the 
transcription factor NF-Y, increasing the expression of NF-Y target genes involved in cell cycle 
control (Cyclin A, Cyclin B2, cdk1, cdc25C).64 Another GOF activity of mutp53 increases the 
expression of hsMAD1, whose levels are correlated with the proliferative status of the cell.93 It 
has been recently demonstrated a novel GOF activity of mutp53 by which it upregulates 
REGγexpression. REGγ is a subunit of the 11S activator, which binds and activates the 20S 
proteasome to degrade specific proteins, such as cell-cycle inhibitors, promoting cell 
proliferation.94 Mutp53 binds to the promoter of ID2, a member of the inhibitor of 
differentiation or DNA binding (Id) family, and downregulates its expression, leading to 
enhanced cell proliferation.95 Mutp53 has also been demonstrated to induce proliferation by 
binding MAP2K3 promoter and  activating its transcription.164 
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The tumour microenvironment. 
The tumour microenvironment (TME) is a concept in evolution that defines the behavior of 
cancer not only by the genetics of the tumour cells, but also by the surrounding milieu needed 
for survival, growth, proliferation, and metastasis.96 The TME is a dynamic network composed 
by cancer cells, stromal tissue (immune cells, fibroblasts, adipocytes, cytokines, and vascular 
tissue), as well as the extracellular matrix that surrounds it all.97  
Cancer cells 
The environment surrounding cancer cells is deficient in oxygen, low in nutrients and glucose, 
and is usually characterized by a low pH.97,98 Cancer cells have adapted for survival in these 
conditions and in some cases use these harsh conditions to their benefit.99,100 For example, 
cancer cells are able to convert from aerobic to anaerobic metabolism in order to survive to the 
hypoxic environment and to fluctuating oxygen tension.101 Cancer cells generate bicarbonic and 
lactic acids (lactate is the principal end product of glycolysis). Such acidic microenvironment 
favor tumour invasion102  and suppress anticancer immune effectors.103 
HIF-1 is a transcription factor that is activated under hypoxia. It has been shown to promote the 
transcription of genes that enable the switch from oxidative phosphorylation to fermentation 
for energy production. Many of these target genes are enzymes of the glycolytic pathway.104,105 
A large number of genes target of HIF-1  promotes tumour growth in hypoxic conditions.100 For 
example, vascular endothelial growth factor (VEGF), erythropoietin, and nitric oxide synthase 
(NOS) are all activated by HIF-1. Thus, HIF-1 is also implicated in angiogenesis.  
Cancer cells modulate the TME by the production of secretory factors such as Matrix 
Metalloproteinases (MMPs). Recently it has been demonstrated that breast cancer cells can 
produce MMP-9, which promotes tumour vascularization and invasion.106  
Cytokines are also differentially produced by tumour with respect to normal cells. For example, 
breast cancer cell lines produce a variety of proinflammatory cytokines with respect to human 
mammary epithelial cells. Among these, markedly up-regulated IL-6, RANTES and, MCP-1 
cytokines are associated with tumour progression and macrophage activation.107 
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Stromal cells 
The TME contains not only malignant cells but also fibroblasts, immune cells, the tumour 
vasculature and lymphatic vessels, as well as, pericytes and sometimes adipocytes.108  
Cancer associated fibroblasts  
Cancer-associated fibroblasts (CAFs) are the most prominent cell type within the tumour 
stroma of various cancers, most notably breast, prostate and pancreatic carcinoma.109,110 CAFs 
differ from normal fibroblasts and may arise during disease progression under the effect of 
cytokines delivered/produced in the milieu, eliciting pro-tumourigenic functions.109 CAFs 
produce a variety of secretory factors that sustains tumour progression, e.g. Tumour growth 
factor β (TGF-β) that has been reported to induce EMT in malignant cells and contributes to the 
immune-suppressive microenvironment,111 and CXCL12 (SDF1-a), a chemokine that can induce 
angiogenesis and enhance cancer cells proliferation.112  
Cells of the immune system 
Tumour associated macrophages  
Most solid tumours recruit macrophages through the production of specific cytokines and 
chemokines, such as colony-stimulating factor 1 (CSF1), vascular endothelial growth factor A 
(VEGFA), semaphorin 3A (SEMA3A), CC-chemokine ligand 2 (CCL2) and CXC-chemokine ligand 
12 (CXCL12).113-115 Tumour associated macrophages (TAMs) present into the tumour milieu 
interact with a wide range of growth factors, cytokines and chemokines, which are thought to 
educate the TAMs to assume a specific phenotype and, consequently, a functional role as 
tumour promoter.116 Macrophages range from M1 to M2 polarization, with M1 producing pro-
inflammatory cytokines with a tumouricidal role and M2 producing immunosuppressive 
cytokines. TAMs resemble M2 macrophages,115 they carry on their tumour-promoter role by 
influencing important aspects of tumour biology: they produce molecules (e.g. EGF) that affect 
cell growth directly, regulate inflammatory responses and adaptive immunity, enhance 
angiogenesis, and catalyze changes of the ECM structure.113,117,118 The M2 polarization factors 
are IL-4, IL-6, IL-10 and IL-13, M-CSF, glucocorticoids, TGFb and prostaglandin E2 (PGE2). These 
factors can be produced by neoplastic cells and fibroblasts (e.g. IL-10, TGF-b), and by Th2 
lymphocytes (e.g. IL-4,IL-13).119 
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Tumour associated neuthrophils. 
Neutrophils recruited into human tumours mileu occurs mainly in response to interleukin-8 
(IL8), which is strongly induced by hypoxia.120 The contribution of tumour-associated 
neutrophils (TANs) to primary tumour growth and metastasis is controversial. Evidences 
indicate TANs promote tumour growth in mouse cancer models and have pro-tumourigenic 
effects by enhancing angiogenesis, immune suppression and increasing degradation of the 
extracellular matrix (ECM).121-124 By contrast, following immunological or cytokine activation, it 
has been observed TANsantitumoural functions . Under these conditions, neutrophils can 
actively eliminate disseminated tumour cells, as well as indirectly through inhibition of TGF-
b.125-128 
T lymphocytes 
Many different T cell populations infiltrate the tumour milieu at the invasive tumour margin 
and in draining lymphoid organs.  
CD8+ memory T cells:  are antigen ‘experienced’ cells with capability of killing tumour cells. 
They are strongly associated with a good prognosis.129 
CD4+ T helper 1 (TH1) cells: are characterized by the production of the cytokines interleukin-2 
(IL-2) and interferon gamma (IFN-γ); elevated numbers of these cells in the TME correlate with 
a good prognosis.129 
CD4+ T helper 2 (TH2) and T helper 17 (TH17) cells:  TH2 cells producing IL-4, IL-5 and IL-13, 
which support B cell responses, or TH17 cells, producing IL-17A, IL-17F, IL-21 and IL-22 that 
favor antimicrobial tissue inflammation, are generally thought to promote tumour growth.129  
CD4+ T regulatory cells (Tregs):  exert an immune suppressive function by producing IL-10, 
transforming growth factor beta (TGF-b) and by cell-mediated contact through cytotoxic T-
lymphocyte antigen 4 (CTLA4), inhibiting recognition and clearance of tumour cells by the 
immune system.130 High numbers of Tregs in the TME correlate with bad prognosis in many 
types of cancer.131,132 
γδ T lymphocytes: have a strong cytotoxic activity against a wide range of malignant cells, 
including cancer stem cells.133,134 it is not yet certain whether the presence of γδ T cells in the 
TME reflects a good or bad prognosis. 
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B lymphocytes 
B lymphocytes are important mediators of humoral immunity. They can promote cancer 
progression by secreting pro-tumourigenic cytokines and altering TH1-to-TH2 ratios. Their 
importance in supporting tumour growth is evident in B cell–deficient mice, which exhibit 
resistance to engraftment of certain syngeneic tumours.135-137 
Natural Killer cells (NK) 
The ability of NK cells to contribute to host control of hematologic malignancies has been well-
documented but recent work has indicated that NK cells also can contribute to control  solid 
tumours. The Interleukin 15 (IL-15) released by tumour cells and IL-15 receptor α (IL-15Rα) 
expressed on cancer cells are fundamental to induce NK cells to destroy tumour cells in mouse 
models.138 A substantial body of evidence suggest that the recognition by the NK receptor 
NKG2D of Rae-1 family ligands in the mouse or the MICA and MICB ligands in humans 
contribute to tumours cells recognition by the immune system.139-141 However, although they 
are present in the TME, NK cells might not be able to exert their tumour-killing function. Studies 
showed that NK cells in the tumour stroma have an anergic phenotype that is induced by 
malignant cell-derived TGF-β.129 
Myeloid-derived suppressor cells (MDSCs) 
MDSCs are immunosuppressive precursors of dendritic cells, macrophages and granulocytes. In 
cancer milieu they mainly function to disrupt tumour immunosurveillance by interfering with T 
cell activation, cytotoxic activity, antigen presentation and cell polarization.136,142  
Dendritic cells (DCs) 
DCs have important functions in antigen processing and presentation. The DCs found in the 
TME are thought to be defective because they cannot stimulate an immune response to 
tumour-associated antigens. The hypoxic and inflammatory TME further impairs DC function to 
activate immune function, and some DCs have been found to suppress T cell responses at the 
tumour site.136 
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Adipocytes 
In some cancers (e.g. intra-abdominal tumours that metastasize to the omentum), adipocytes 
actively aid the recruitment of malignant cells through the secretion of adipokines and also 
promote the growth of malignant cells by providing fatty acids as fuel for the cancer cells.143 
Adipose stromal cells can be recruited to growing tumours, where they can also differentiate 
into pericytes and incorporate into vessel walls.144 
Cancer-releated inflammation in tumour promotion 
It is well established that chronic-inflammation predisposes to different forms of cancer, but 
inflammatory components are also present in the microenvironment of most neoplastic tissues 
for which a firm causal relationship to inflammation has not been established, indicating that a 
chronic-inflammatory microenvironment can also promote tumour progression. The hallmarks 
of cancer-related inflammation include the presence of inflammatory cells and inflammatory 
mediators (e.g. chemokines, cytokines and prostaglandins) in tumour tissues with tissue 
remodeling and angiogenesis similar to that seen in chronic-inflammatory responses, and tissue 
repair.117 
An important transcription factor involved in cancer inflammation is nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB). The NF-κB and inflammation have generally a 
double role in cancer. On one hand, NF-κB activation is part of the immune defense, which 
eliminates transformed cells, in particular during acute inflammatory processes, where the 
activation of NF-κB is accompanied by a high activity of cytotoxic immune cells against cancer 
cells.145 On the other hand, NF-κB is constitutively activated in many types of cancer and can 
exert a variety of pro-tumourigenic functions. These cancers seems to be characterized by a 
chronic-inflammatory condition with often only moderately elevated levels of NF-κB activity. 
NF-κB induces cytokines that regulate the immune response (such as TNFα, IL-1, IL-6 and IL-8), 
as well as adhesion molecules required for the recruitment of leukocytes to the inflammation 
sites. NF-κB signaling was shown to control a great variety of other cellular processes, including 
cell proliferation,146,147 apoptosis,148 EMT and metastasis,149 and angiogenesis (via upregulation 
of VEGF and its receptors).150,151 Enhanced NF-κB activity can be directly induced by mutations 
of NF-κB genes and/or oncogenes that activate the NF-κB signaling pathway, or through 
increased cytokine release from the TME.152 In the canonical activation pathway, excitatory 
signaling can be mediated through Toll-like receptors (TLRs), Interleukin-1 receptor (IL-1R), 
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tumour necrosis factor receptor (TNFR) and antigen receptors. Typical stimulating signaling 
molecules are tumour necrosis factor α (TNFα) and interleukin-1 β (IL-1β).153,154 
 IL-1β is a pro-inflammatory cytokine that can be produced by malignant or microenvironmental 
cells. IL-1β is involved in all phases of the malignant process, such as tumourigenesis, tumour 
invasiveness, progression, as well as activation/suppression of anti-tumour immunity. In the 
malignant process, IL-1 activates pre-malignant, malignant cells, as well as surrounding cells of 
the microenvironment which induces production of inflammatory mediators, such as growth 
factors, MMPs, angiogenic factors  (VEGF) and  cytokines (IL-8, MCP-1), with which promote 
growth and invasiveness. In experimental tumour models and in cancer patients, increased 
local levels of IL-1 usually correlate with tumour invasiveness and a bad prognosis.155  
The pro-inflammatory cytokine TNF-α has a critical role in chronic-inflammatory diseases. 
Although originally shown to be toxic to tumour cells at high doses, the tumour-promoting 
function of TNF-α has been clearly demonstrated in mice.156 TNF-α has been shown to 
contribute in tumour initiation and progression by stimulating the production of genotoxic 
reactive nitrogen/oxigen species (RNS/ROS). Tumour  or inflammatory cells in the TME throught 
TNF-α production can  promote cell survival, invasion, angiogenesis, impair the immune 
surveillance through T-cell suppression and inhibition of the cytotoxic activity of activated 
macrophages.157  
Mutant p53 in the tumour microenvironment. 
In recent years there has been increased attention on the potential role of mutp53 in the TME 
modulation . Indeed, expression of mutp53 in surrounding stromal fibroblasts enhances tumour 
growth and facilitates metastasis in prostate tumour.158  
Malignant cells are able to induce angiogenesis in order to respond to the growing demands of 
nutrients and oxygen by the tumour mass. There is indeed a correlation between mutp53 and 
VEGF expression and tumour aggressiveness.159,160 To facilitate angiogenesis, mutp53, together 
with E2F1, were found to induce the expression of ID4, which in turn promotes the expression 
of pro-angiogenic factors such as IL-8 and GROα, leading to augmented angiogenesis of the 
cancerous tissue.161 Accordingly, mutp53 depletion reduces growth, stromal invasion and 
angiogenesis in  xenograft tumours87.  
Recently it has also been demonstrated a relation between mutp53 and cancer inflammation. 
Indeed, mutp53  augments and prolongs the response of epithelial cells to low amounts of 
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inflammatory cytokine, enforcing a chronic state of NF-kB activation, contributing to the 
expression of NF-kB pro-inflammatory target genes (Cooks et al 2013). By binding and inhibiting 
the tumour suppressor DAB2IP in the cytoplasm of cancer cell lines, mutp53 fuels NF-kB 
activation while it dampens activation of ASK1/JNK by TNF-α.71 GOF activities of mutp53 
proteins were also found to upregulate CXC-chemokine expression contributing to multiple 
aspects of tumourigenesis.162  
 
 
 
 
 
17 
 
Chapter 2        
Aims of the study 
 
A previous work published by Bossi et al.,87 showed that conditional depletion of mutp53 in 
vivo reduces tumour growth, angiogenesis and stromal invasion in HT29 xenograft tumours, 
suggesting a potential role of mutp53 in supporting tumour growth and progression by 
modulating the TME .  
To investigate the mutp53/TME crosstalk, the first part of my study aimed to explore whether 
mutp53 might have roles in the modulation of cancer cell secretome. Following secretory 
factors identification, studies in vitro and in xenograft models have been performed to 
understand the molecular mechanisms responsible for the mutp53 dependent regulation and 
the biological significance in mutp53 GOF . 
To deeply understand the role of mutp53 in TME modulation, the identification of more 
physiological experimental models  would be desirable. Indeed, the immune system is 
considered as a double edge sword that helps fight cancer but can also support   its 
progression. For these reasons, the second part of the study has been performed by using 
immunocompetent mice. To this aim, subsequent studies have been addressed in  genetically 
engineered mice carrying the p53R172H mutation corresponding to the human host-spot 
p53R175H. Since R175H is the second most common site of missense mutation in human breast 
cancer, the mutp53/TME crosstalk has been investigated in breast cancers chemically induced 
(MPA-DMBA) in wtp53 and mutp53R172H knock-in mice. 
Given that suitable murine breast cancer lines to analyze mutp53/TME crosstalk are currently 
missing, the final part of my studies aimed at the generation and characterization of a 
syngeneic orthotopic model of breast cancer in immunocompetent mice. This model would 
allow to validate the relevance of cellular or molecular players that will be  identified as 
significantly involved in mutp53 driven TME modulation. 
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Chapter 3        
Materials and Methods 
 
Cell culture 
Human lines HT29 (colon adenocarcinoma), MDA-MB468 (breast adenocarcinoma), SKBR3 and 
MDA-MB231 (breast adenocarcinoma), engineered with an lentiviral-based TET-OFF inducible 
RNAi system carrying sh-RNA sequences specific for p53 (sh-p53) or control scrambled (sh-scr), 
are previously described.87,164 HEPG2 (hepatocellular carcinoma) and MCF7 (breast 
adenocarcinoma) cells were purchased from ATCC (Manassas, VA, USA). All but MDA-MB231 
and MCF7 cells, cultured in Dulbecco’s modified Eagle’s medium (DMEM)-F12 1:1, were 
cultured in DMEM supplemented with 10% fetal bovine serum (GIBCO-BRL, Grand Island, NY, 
USA), L-glutamine (2mM) and Penicillin/Streptomycin (100 U/ml) (Life Technologies Inc., 
Eggenstein, Germany). HUVEC cells (Lonza, Basel, Switzerland), cultured in endothelial cell basal 
medium (EBM-2) supplemented with endothelial cell Bullet Kit (Lonza), were used between 
passages 4 and 5 for experiments.165 All cells were grown at 37 °C in a humidified atmosphere 
with 5% CO2. 
Cytokine arrays 
To generate CMs, engineered sh-p53 and sh-scr HT29, MDA-MB468, SKBR3 or MDA-MB231 
cells were cultured 72 h with plus/minus (±) tetracycline derived DOX (1.0 μg/ml) (D9891, 
Sigma-Aldrich, Milan, Italy) to induce sh-RNA expression. Then, cells were seeded (6.0 
×105/60mm dish) and 24 h later washed (3×) in phosphate-buffered saline (PBS) before refed 
with fresh DMEM± DOX. Seventy-two hours later, CMs were collected and analyzed with non-
magnetic BIOPLEX-HU-27-PLEX kit (171A11127, Bio-Rad, Hercules, CA, USA) and Bio-Plex200 
instrument, equipped with the Bio-Plex Manager Software 4.1 following the manufacturer’s 
guidelines. 
Semi-quantitative and quantitative reverse transcriptase–PCR 
TRIzol (15596-026; Invitrogen, Monza, Italy) extracted RNAs from cells or tumors were retro-
transcribed with Moloney-Murine-Leukemia virus reverse-transcriptase (M-MLV-RT, Invitrogen) 
following the manufacturer’s instruction. 
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For semiquantitative PCR, cDNAs were amplified by Hot-Master Taq (5PRIME) with: hGAPDH 
(human glyceraldehyde 3-phosphate dehydrogenase; FOR 5'-ATGACATCAAGAACGTGGTG-3', 
REV 5’-CATACCAGGAAATGAGCTTG-3′); hp53 (FOR 5'-GTCTGGGCTTCTTGCATTCT-3'), REV 5'-
AATCAACCCACAGCTGCAC-3'); mMCP-1/CCL2 (FOR 5'-AAGCTGTAGTTTTTGTCACCAAGC-3', REV 
5'-TGCTTGAGGTGGTTGTGGAA-3'); mGAPDH (FOR 5'-GCCTGGAGAAACCTGCCAA-3', REV 5'-
TTATGGGGGTCTGGGATGGA-3'). For qPCR, cDNAs were amplified with SYBR reagent in a real-
time PCR machine (ABI 7900; Applied Biosystems, Foster City, CA, USA) with 50 cycles of two-
step amplification with the following primers: hsIL1RA (FOR 5'-TTCCTGTTCCATTCAGAGACGAT-
3', REV 5'-CCAGATTCTGAAGGCTTGCAT-3'); hIL-8 (FOR 5'-CTCTGTCTGGACCCCAAGGA-3', REV 5'-
TGAATTCTCAGCCCTCTTCAAAA-3'); hMAFF (FOR 5'-TGCCCAGGTCCCATTTCTC-3', REV 5'-
GGCCCACGAAGGGAATGT-3'); and hβ-actin FOR 5'-GCTGCCCTGAGGCACTCTT-3', REV 5'-
ATGATGGAGTTGAAGGTAGTTTCGT-3'). All reactions were performed in triplicate in a final 
volume of 20 μl. Dissociation curves were run to confirm that single products were amplified in 
each reaction. QPCR data were analyzed using the 2^ − ΔCt method: 2^ − ΔCt = 2^ − (Ct target –
Ct reference) where Ct target and Ct reference (hBeta-actin) are mean threshold cycles of PCR 
done in triplicates on the same cDNA samples. The relative mRNA levels with respect to control 
samples (set to 1.0) were obtained by the ratio 2 ^− ΔCt sample/2^ − ΔCt control sample. 
Western blotting 
Cells, rinsed (2×) with ice-cold PBS, were lysed in 1 × RIPA buffer16 supplemented with 
protease/phosphatase inhibitors cocktail (Sigma-Aldrich). Lysates (30μg/lane) were resolved on 
10% or 13% SDS–PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis), and filters 
were immuno-reacted with the following antibodies: mouse anti-p53 (DOI),6 rabbit anti-MAFF 
(M8194, Sigma-Aldrich), mouse anti-actin (Ab-1, Calbiochem, Billerica, MA, USA), rabbit anti-
hIL-1R1 (EP409Y, Epitomic, Burlingame, CA, USA); and rabbit anti-p21 (sc-397, Santa Cruz 
Biotechnology, Dallas, TX, USA). To detect sIL-1Ra production, CMs, concentrated with 
Centricon-10 (4205-Amicon) following the manufacturer’s instruction, were supplemented with 
loading dye (Tris/HCl pH6.8, Glycerol and Bromophenol- Blue) and resolved by 13% SDS–PAGE. 
Filters were immuno-reacted with rabbit anti-hsIL-1Ra (ab2573, Abcam, Cambridge, UK). 
Secondary HRP-conjugated anti-mouse (Santa Cruz Biotechnology) or anti-rabbit (Calbiochem) 
antibodies and ECL kit (Amersham Biosciences Glattbrugg, Switzerland) were used to detect 
immuno-reactions. Images were acquired with the EPSON Expression 10000 XL scanner (Epson, 
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Long Beach, CA, USA), and densitometry was performed with the ImageJ software (NIH, 
Bethesda, MD, USA). 
Transfection and luciferase reporter assay 
Early transduced sh-scr and sh-p53 HT29 and MDA-MB468 cells16 were seeded (5 × 104cells/6 
well plate) and 24 h later transfected with pRA-1680-Luc17 (0.8 μg/well) and pRSVβ-GAL16 (0.2 
μg/well) vectors with lipofectamine/plus reagents (Invitrogen) following the manufacturer’s 
guidelines. Cells were processed 48 h later. MCF7 cells were seeded (2 × 105/60mm dish) and 
transfected with pRa-1680-Luc (8 μg/dish) and pRSVβ-GAL (2 μg/dish) by calcium phosphate 
procedure. After 24 h, cells refed with fresh medium were either treated with Nut-3 (10 μM, 
10004372 Cayman) or DMSO and collected 48 h later. HEPG2 cells were seeded (2 × 105/60mm 
dish) and co-transfected with pRA-1680-Luc (7 μg/dish) and pRSVβ-GAL (2 μg/dish) along with 
either empty, wtp53, p53R273H or p53R175H encoding vectors (1 μg/dish). Twenty-four hours 
after medium replacement, cells were treated with LPS (30 ng/ml; Escherichia Coli 055: B5, 
Sigma-Aldrich) and processed 48 h posttransfection. Luciferase and β-galactosidase assays were 
performed as reported earlier.164 
ChIP assays 
Cells upon treatments were cross-linked as reported.164 Sonicated chromatins were incubated 
with the following antibodies: rabbit anti-p53 (6 μl/reaction; ab-7 no. PC35, Oncogene, Billerica, 
MA, USA); rabbit anti-MAFF (8 μl/reaction; M8194, Sigma-Aldrich); goat anti-GFI-1 (4 
μg/reaction; sc-8558, Santa Cruz Biotechnology); goat anti-HRT1 (4 μg/ reaction; sc-16424, 
Santa Cruz Biotechnology); anti-PAN-H3ac (10 μl/ reaction; no. 06-599, Millipore, Billerica, MA, 
USA); anti-H3K9ac (4 μl/reaction; no. 07-352, Upstate, Billerica, MA, USA); anti-H3K14ac (4 μl/ 
reaction; no. 07-353, Upstate); and anti-H3K4me3 (8 μl/reaction; no. 07-473, Upstate). ChIP-
enriched DNA was determined with semi-quantitative and qPCR. Semi-quantitative PCRs were 
performed with Hot-Master Taq (5PRIME) and the following primers: hsIL-1Ra-I (FOR 5'-
CTGGGATTACAGGCACATGC-3'; and REV 5'-TGTCTCCTTGGCCCTCAAAG-3'). QPCR were 
performed with SYBR reagent in a real-time PCR machine (ABI 7900; Applied Biosystems) with 
50 cycles of two-step amplification and the following primers: hsIL-1Ra-I (FOR 5'-
CCAGCCCAGCCATCATTTT-3'; REV 5'-TTGGCCCTCAAAGGAAGACA-3'); hsIL-1Ra-II (FOR 5'-
GGGTGGCACAAGGCAAGT-3'; REV 5'-AACTCAGCATTTGGACAGGAATG-3'); hsIL-1Ra-III (FOR 5'-
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CCAAGGCTGTCCATTTTTCAA-3'; REV 5'-GATAGGGCTCCCTGCACATG -3′); and hsIL-1Ra-IV (FOR 
5'-GCTTGGGTGAGTGACTATTTCTTTATAA-3'; REV 5'-TCCATTCTGTGACTGCAGCAA-3'). All 
reactions were performed in triplicate in a final volume of 20 μl. Dissociation curves were run to 
confirm that single products were amplified in each reaction. QPCR data were analyzed using 
the 2 − ΔΔCt method (fold enrichment relative to the NoAb); this includes normalization for 
both background levels and input chromatin: 2^ − ΔΔCt = 2^− (ΔCtIP − ΔCtnoAb), where ΔCtIP = 
CtIP – Ctinput and ΔCtnoAb = CtnoAb-Ctinput. CtIP and CtnoAb are mean threshold cycles of 
PCR done in triplicates on DNA samples immunoprecipitated with specific antibody and control 
(noAb) defined as 1.0.164 
Co-IP 
Cells, washed (2 × ) with cold PBS, were collected with prechilled lysis buffer (PBS pH8.3; 10mM 
EDTA; 0.1% Tween20) supplemented with protease/phosphatase inhibitors and lysate on ice by 
passing cell suspension through a 26-G needle several times. Lysates (1 mg/sample) were 
clarified (16 000 g, 10 min at 4 °C), precleared with Pierce Protein-G Agarose (20399, Thermo-
Scientific, Waltham, MA, USA) and incubated (overnight at +4 °C) with either rabbit anti-MAFF 
(4 μl/sample, M8194 Sigma-Aldrich) or rabbit IgG (2729, Cell Signaling, Danver, MA, USA) 
antibodies. The day after, washed Protein G slurry (50 μl/sample) was added, and samples were 
incubated for 45 min at 4 °C. After washes (2× ) in cold lysis buffer, samples were resolved in 
10% SDS–PAGE, and filters were incubated with p53 (DO1) and MAFF-specific antibodies. 
MAFF RNAi 
Human MAFF shRNA-specific sequence (RNAi-codex-portal/database)164 (5'-
cgcgtccCTATCCAGCAAAGCTCTAAttcaagaga-TTAGAGCTTTGCTGGATAGtttttggaaat-3'; 5'-
cgatttccaaaaaCTATCCAGCAAAGCTCTA-AtctcttgaaTTAGAGCTTTGCTGGATAGa-3'), were annealed 
and cloned into MluI/ClaI (Roche Applied Science, Basilea, Switzerland) digested pLV-THM 
vector generating pLV-THsh/MAFF. Lentivirus was produced and titered as described.87 For 
constitutive RNAi, cells were transduced at required MOI with polybrene (8.0 μg/ml) (Sigma-
Aldrich, H-9268). After 16 h, cells were washed and replenished with fresh medium and 
cultured until processing. Stealth RNAi si-RNA duplex oligo ribonucleotides (Invitrogen Life 
Technologies) MAFF-specific or negative control were transduced with INTERFERin (Polyplus 
transfection) following the manufacture’s guidelines. Cell were processed 48 h later. 
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IL-8 gene expression 
Sh-scr and sh-p53 HT29 and MDA-MB468 cells, cultured 72 h with DOX (1 μg/ml), were seeded 
(2.5 × 105 cells/six-well plate) and 24h later washed 3 × ) in PBS before refed with DMEM+DOX. 
Cells were cultured 72h for medium conditioning and then incubated (1 h) with either 
recombinant human IL-1β (rhIL-1β; 400-002; RELIATech GmbH) or vehicle solution (PBS+0.1% 
bovine serum albumin). For neutralization assays, before rhIL-1β delivery sh-scr cells were 
pretreated (2h) with recombinant nonglycosylated human sIL-1Ra (0.2 and 0.5 μg/ml; anakinra, 
Kineret, SOBI, Stockholm, Sweden). After incubations, IL-8 gene expression was verified by 
qPCR.  
Endothelial cell injury 
Sh-scr and sh-p53 HT29 and MDA-MB468 cells, cultured 72 h with DOX, were seeded (1.5 × 106 
cells/100mm dish) and 24h later washed (×3) in PBS before refed with DMEM+DOX. After 72h, 
all cells were incubated (6h) with either rhIL-1β or vehicle solution, along with Kineret 
pretreatment as described above. After incubations, CMs were collected and delivered (1:10 
diluted in serum-free EBM-2) to 24h cultured HUVEC cells (1.5 × 105 cells/60mm dish). Cell 
viability was assessed 24h later by trypan-blue.  
Bromodeoxyuridine incorporation assays 
Sh-scr and sh-p53 HT29 and MDA-MB468 cells, cultured 72h with DOX, were seeded (1 × 105 
cells/35mm dish) and 96h later incubated (6h) with either rhIL-1β or vehicle solution, along 
with Kineret pretreatments as described above. After BrdU (20 μM; Sigma-Aldrich) incubation 
(2h) cells were processed as described.192 The percentage of BrdU-positive nuclei were 
estimated by counting 500 cells per field, five fields for each experimental condition.  
Xenograft in vivo assay  
Exponentially growing sh-scr and sh-p53 HT29 (5 × 105 cell/mouse) or MDA-MB468 (5 × 106 
cells/mouse) cells were either injected (8 mice/group) subcutaneously in 45-days-old (20–23 gr) 
female nude mice (CD1/Swiss, Charles River, Lecco, Italy). After tumor appearance, all mice 
received DOX (2.0 g/l) as reported.6 LPS (1 μg/mouse, intraperitoneal) was delivered in 
physiological water to all mice, whereas Kineret (0.2 μg/mouse in DMEM) was delivered in peri-
tumoral region to a subgroup of sh-scr tumor-bearing mice 1 h after LPS administration. 
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Treatments were performed three times a week till the end of the experiment. Tumor growth 
was followed by caliper measurements twice a week and tumor volumes were (TV) estimated 
by the formula: TV = a × (b2)/2, where a and b are tumor length and width, respectively. All the 
procedures involving animals and their care were approved by the Ethical Committee of the 
Regina Elena Cancer Institute (CE/532/12) and were conformed to the relevant regulatory 
standards in accordance with the Italian legislation. 
Chemical induction of mammary tumours   
C57BL/6 +/R172H mice166 were backcrossed with FVB+/+ mice for 3 generations (N3) obtaining 
mice with a 87,5%  FVB and 12,5% with C57BL/6 background. To obtain p53+/R172H, p53R172H/R172H  
and p53+/+ female mice,  we crossed heterozygous FVB p53+/R172H N3 brothers and sisters. The 
F1 female mice were used to the chemical induction of mammary tumours. A MPA 
(medroxyprogesterone acetate ) pellet (35 mg) has been implanted into the interscapular area 
of p53+/R172H, p53R172H/R172H  and p53+/+ 6-weeks old female mice. Mice were then treated with 
DMBA (Dimethylbenz(a)anthracene) (1mg/dose dissolved in seed oil, by oral gavage 
administration) at weeks 9,10,12,13.168 Mice were euthanized when the primary tumor reached 
a volume of 1,0 cm3. Tumours were exiced, and each sample was both snap frozen in liquid 
nitrogen and stored at -80°C (For RNA analysis), and fixed in Formalin, Buffered, 10% (for 
immunohistochemical analysis). 
DNA extraction from tails biopsies 
3 mm of mouse tails were digested with DNA digestion buffer (50 mM Tris-HCl pH 8.0, 100 mM 
EDTA pH 8.0, 100 mM NaCl, 1% SDS, 0.5 mg/ml proteinase K (Life technologies)) and incubated 
overnight at 53°C with gentle shaking. DNA was then extracted by phenol/chloroform/isoamyl 
alcohol (25:24:1), precipitated in 100% ethanol, washed in 70% ethanol and resuspended in 
H2O. 
Genomic DNA genotyping 
Genotyping was performed by PCR analysis using 50 ng of genomic DNA and the following 
primers: FOR 5'-ACCTGTAGCTCCAGCACTGG-3', REV 5'-ACAAGCCGAGTAACGATCAGG-3' . PCR 
reactions consisted of 35 cycles of 95 °C for 60 s, 60 °C for 60 s and 72 °C for 180 s and run on 
2% agarose electrophoresis gel. 
24 
 
Generation of the mutant p53 murine breast cancer cell line (44-1 cell line) 
A part of an exciced chemically induced tumour derived from a p53R172H/R172H mouse has been 
cut in small pieces, treated with trypsin-EDTA supplemented with Penicillin/Streptomycin (100 
U/ml) for 1h at 37°C in a humidified atmosphere with 5% CO2, in gentle agitation. Cell 
suspension has been then plated in RPMI-1640 supplemented with 20% fetal bovine serum 
(GIBCO-BRL, Grand Island, NY, USA), L-glutamine (2mM) and Penicillin/Streptomycin (100 U/ml) 
(Life Technologies Inc., Eggenstein, Germany) for 48h in a humidified atmosphere with 5% CO2. 
Fibroblasts were then removed by mild trypsinization. The derived cancer cell line, named 44-1, 
has been maintained as a mixed population in RPMI-1640 supplemented with 20% fetal bovine 
serum (GIBCO-BRL, Grand Island, NY, USA), L-glutamine (2mM) and Penicillin/Streptomycin 
(100 U/ml) (Life Technologies Inc., Eggenstein, Germany) in a humidified atmosphere with 5% 
CO2.  
Generation of the orthotopic model of breast cancer 
Exponentially growing 44-1 cells (1 × 106 cell/mouse) were injected into the fat pad of the 
mammary gland of anesthetized 6-weeks old female FVB +/+ mice. Tumor growth was followed 
as described above. At the end of the experiments, mice were euthanized and tumours exiced, 
and each sample was both snap frozen in liquid nitrogen and stored at -80°C (For RNA analysis), 
and fixed in Formalin, Buffered, 10% (for immunohistochemical analysis). 
Immunohistochemestry 
Animals were sacrificed and tumours collected and processed for histological analysis, using 
standard methods and after staining with Hematoxylin & Eosin (H&E) the sections were 
analyzed. For immunohistochemical analyses, 3-μm thick tumour sections were dewaxed, 
rehydrated then incubated in 0.3% H2O2 in methanol for 30 min to inhibit endogenous 
peroxidase. After antigen unmasking, carried out according to the manufacturer’s instructions, 
sections were incubated overnight at + 4°C with the following primary antibodies: Rat 
monoclonal [CI:A3-1] to F4/80 (abcam), Rat monoclonal [RB6-8C5] to Ly6g (abcam), Anti-p53 
(Ab-7) (Pantropic) Sheep pAb. Detection was carried out with the Vectastain Elite ABC Kit 
(Vector Laboratories, Inc., Burlingame, CA), by using anti-rat or anti-sheep biotinylated 
secondary antibodies respectively, for 1h at room temperature. After incubation with avidin-
biotin immunoperoxidase, immunohistochemical staining was visualized with 3-amino-9-
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ethylcarbazole (Vector Novared kit; Vector Laboratories, Inc.). Slides were counterstained with 
Mayer’s haematoxylin and mounted in Glycergel (Dako Corporation, Carpinteria, CA, USA) for 
microscopy. 
Statistical analysis 
All experiments were performed in triplicate. Numerical data are reported as means ± s.d.s. 
Significances were assessed by the Student’s t-test analyses. 
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Chapter 4        
Results-part 1 
 
Mutant but not wild-type (wt) p53 suppresses sIL-1Ra gene expression in tumour cells  
Previous studies showed that the inducible  depletion of mutp53 in HT29 xenograft tumours 
reduces tumour growth, angiogenesis and stromal invasion.87 Based on this, we enquired 
whether mutp53 might exert novel, unidentified roles in the regulation of TME. To address this 
issue, we investigated the cytokines production in a panel of human cancer lines, harboring 
different p53 hot-spot mutations, earlier engineered with a lentiviral-based TET-OFF inducible 
RNAi system encoding p53 (shp53) or scrambled (sh-scr) shRNA-specific sequences.87,164 
Conditioned media (CMs) were generated from sh-p53 and sh-scr cells treated/untreated with 
doxycycline (DOX), a tetracycline analog. Cytokines profile showed that mutp53 affects the 
production of specific cytokines. Indeed, a significantly higher production of secreted 
Interleukin-1 Receptor Antagonist (sIL-1Ra) was found in CMs of HT29 (colon adenocarcinoma) 
and MDA-MB468 (breast adenocarcinoma) cancer cells upon depletion of endogenous 
p53R273H (sh-p53+DOX) with respect to controls (sh-p53; sh-scr+DOX) (Fig. 2A). Interestingly, 
no significant effects were observed in MDA-MB231 (breast adenocarcinoma) and SKBR3 
(breast adenocarcinoma) cells upon depletion of their R280K and R175H mutants, respectively 
(Fig. 2A). Further analyses confirmed the increased sIL-1Ra production seen in mutp53R273H 
depleted cells at mRNA level (Fig. 2B) and as secreted protein (Fig. 2C). The sIL-1Ra is encoded 
by the IL1RN gene along with the closely related intracellular (ic) IL-1Ra, whose expression is 
controlled by the activity of two separate 5’ regulatory regions.169,170  The sIL-1Ra along with 
the two agonistic proteins IL-1α and β constitutes the IL-1 family.171 The sIL-1Ra acts as a 
specific antagonist of the IL-1 pro-inflammatory cytokines: it binds to both type I and II IL-1 
receptors, with approximately equal affinity as compared with IL-1α and IL-1β, without exerting 
any agonist activity,172  thus blocking or reducing the IL-1 pro-inflammatory signals.  
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Figure 2. Mutant p53R273H suppresses sIL-1Ra protein production in cancer cells. (A) Cytokine arrays performed on CMs generated 
from either engineered sh-p53 and sh-scr HT29, MDA-MB468, SKBR3 or MDA-MB231 cancer lines. Relative sIL-1Ra production was 
quantified with respect to controls (sh-scr-DOX) set to 1.0. Upper panels, western blotting (WB) analyses were performed, on derived 
protein lysates, with the indicated antibodies.(B) Reverse transcriptase–PCR (RT–PCR) (upper panel) and qPCR (lower panel) performed 
on total RNAs from engineered sh-p53 and sh-scr HT29 and MDA-MB468 to assess occurred mutp53 depletion and to analyze effects 
on sIL-1Ra gene expression. Relative sIL-1Ra mRNA level were quantified with respect to controls (sh-scr) set to 1.0.(C) WBs performed 
with the indicated antibody on CMs generated from the indicated cancer cells along with recombinant human sIL-1Ra (Kineret) 
(positive control). 
 
To explore whether the wtp53 protein might have roles in sIL-1Ra gene expression, we 
performed experiments with MCF7 cells upon delivery of Nutlin-3 (Nut-3), a well-known non-
genotoxic wtp53 activator. Activated wtp53, as confirmed by induced p21 expression (Fig. 3A), 
increases significantly the sIL-1Ra mRNA (Fig. 3A, lower panel) and secreted protein (Fig. 3B) 
with respect to cells treated only with the Nut-3 solvent, dimethyl sulfoxide (DMSO). These 
results show that p53R273H suppresses, whereas wtp53 induces sIL-1Ra expression, suggesting 
a novel mutp53 GOF activity. 
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Figure 3. Wt p53 induces sIL-1Ra protein production in cancer cells.(A) MCF7 
cells were treated with either Nut-3 (10 μM) or DMSO, and RNAs and proteins 
extracted 48 h later. (Upper panel) WB analyses performed with the indicated 
antibodies. (Lower panel) qPCR analyses. Relative sIL-1Ra mRNA level were 
quantified with respect to DMSO-treated cells set to 1.0. (B) WBs performed with 
the indicated antibody on CMs derived from MCF-7 cancer cells upon treatment 
with DMSO and Nut-3 as in (B). 
 
Mutant but not wtp53 reduces sIL-1Ra promoter activity 
To investigate whether the increased sIL-1Ra gene expression upon p53R273H depletion or 
wtp53 activation might occur by modulating the sIL-1Ra promoter activity, assays were 
performed with the sIL-1Ra regulatory region driving a luciferase reporter (pRA1680-Luc; − 
1680 bp with respect to transcription start site), which exhibits patterns of expression and 
induction similar to that of the endogenous gene.169 Reporter assays were performed with sh-
p53 and sh-scr HT29 and MDA-MB468 cells and with Nut-3- and DMSO-treated MCF7 cells. 
Significantly higher sIL-1Ra promoter activity was found in mutp53 depleted HT29 and MDA-
MB468 cells and Nut-3-treated MCF7 cells with respect to their controls (sh-scr and DMSO) (Fig. 
4). 
 
 
 
 
 
 
 
 
Figure 4. Mutant p53 inhibits, whereas wtp53 increases the sIL-1Ra gene expression modulating its promoter activity.  The activities 
of sIL-1Ra regulatory region (−1680;+1 with respect to transcription start site) were analyzed in either: (i) early lentiviral-transduced sh-
scr and sh-p53 HT29 and MDA-MB468 cells; and (ii) Nut-3 or DMSO-treated MCF7 cells. Outcomes were normalized to transfection 
efficiency (βGAL) and protein quantity. Relative Luc activity was quantified with respect to controls (sh-scr or DMSO) set to 1.0. 
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To further confirm the achieved results, we analyzed the transcriptional activity of the 
endogenous sIL-1Ra promoter. As shown in Fig. 5, an increased occupancy of active chromatin 
markers was detected in sh-p53 HT29 cells with respect to controls (sh-scr). These results 
indicate that, under our experimental conditions, p53R273H suppresses sIL-1Ra gene 
expression by reducing its promoter activity, whereas wtp53 increases promoter activity.  
 
 
 
 
Figure 5. Endogenous sIL-1Ra promoter activities. Chromatins were 
isolated from sh-scr and sh-p53 HT29 cells, and ChIP assays performed to 
analyze the recruitments of histone H3 pan-acetylated (H3Ac pan); H3 
acetylated at lysine 9 (H3K9ac), H3 acetylated at lysine 14 (H3K14ac) and 
H3 tri-methylated at lysine 4 (H3K4me3) 
 
 
We next asked whether the sIL-1Ra suppression might occur in a p53R273H-specific fashion or 
whether other p53 mutants might similarly affect the sIL-1Ra gene expression. Thus, 
experiments have been  performed in isogenic conditions with HEPG2 cells, a line widely used 
to study the production of acute-phase proteins (APPs), as sIL-1Ra was described as an APP.173 
The sIL-1Ra promoter activity was evaluated upon transient ectopic expression of wtp53, 
p53R273H or p53R175H encoding cDNAs. The results showed that, with respect to control 
(empty vector), exogenous wtp53 significantly increases the sIL-1Ra promoter activity, whereas 
both ectopically expressed mutants inhibit its activity (Fig. 6A). Confirmatory experiments were 
similarly carried out in mutp53 depleted HT29 cells along with exogenous expression of either 
p53R175H or p53R273H mutants. As shown in Fig. 6B, the increased sIL-1Ra mRNA levels 
observed along with depletion of endogenous p53R273H, drops consistently upon p53R175H or 
p53R273H ectopic expression. These results show that mutp53-driven sIL-1Ra suppression 
might not occur in a mutation specific fashion, and the discrepancy with SKBR3 results might be 
related to the cell specificity of mutp53 GOFs. 
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 Figure 6. sIL-1Ra suppression does not occur in a p53R273H-specific fashion. (A) HEPG2 cells were transfected with pRA1680-Luc 
vector along with either empty, wtp53, p53R273H or p53R175H expressing vectors. Cells were processed 48 h later after 24 h of  LPS 
(30 ng/ml) treatments. Upper panel: western blotting analyses performed with the indicated antibodies. Lower  panel: the sIL-1Ra 
promoter activities, analyzed by luciferase assays. Relative Luc activities were quantified with respect to controls (empty vector) set to 
1.0. (B) Engineered sh-scr and sh-p53 HT29 sublines, after 72h incubation with DOX (1.0 μg/ml) were plated and 24h later sh-p53 cells 
were transfected either with p53R175H or p53R273H carrying vectors. 48h  later, total RNAs were isolated and analyzed by PCR 
(GAPDH, p53) and qPCR (sIL-1Ra). Relative sIL-1Ra mRNA levels were quantified with respect to sh-scr RNA set to 1.0. 
 
Mutant but not wtp53 is physically recruited to the sIL-1Ra promoter 
To explore whether mutp53 suppresses sIL-1Ra through the physical interaction with its 
promoter, chromatin immunoprecipitation (ChIP) assays were performed with sh-scr and sh-
p53 HT29 and MDA-MB468 chromatins. To identify putative sIL-1Ra regulatory regions involved 
in mutp53 promoter occupancy, primers were designed to dissect the sIL-1Ra promoter (−1680) 
in four regions (I–IV) (Fig. 8, upper panel). A significant p53R273H recruitment was found in sIL-
1Ra regulatory regions I and III with both lines (Fig. 8). The enrichment was specific as vanished 
in mutp53-depleted chromatins (Fig. 8). We next enquired whether wtp53 could interact with 
the sIL-1Ra promoter. As shown in Fig. 8, no significant enrichment was observed in either 
MCF7 or HCT116 chromatins, indicating that activated wtp53 is not recruited on the sIL-1Ra 
promoter. These results are in agreement with the in silico analyses (MatInspector), which 
showed no wtp53 consensus binding site in examined sIL-1Ra promoter (−1680 bp, data not 
shown). Taken together, these results suggest that while mutp53 could be directly involved in 
the sIL-1Ra suppression, the wtp53 might induce sIL-1Ra expression indirectly, through 
undefined molecular players. 
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Figure 8. Mutant but not wtp53 is physically recruited on the sIL-1Ra promoter. ChIP assays performed with chromatins isolated 
either from sh-p53 and sh-scr HT29 and MDA-MB468 cells, DMSO or Nut-3-treated MCF7 cells or Adriamycin (Adr)-treated HCT116 
cells. ChIP-enriched DNA were quantified by qPCR with set of primers (upper cartoon) designed to dissect the − 1680 sIL-1Ra promoter 
in four regions (I–IV). Relative enrichments were quantified with respect to ‘No Ab’ set to 1.0. 
 
MafF is involved in sIL-1Ra gene expression in both mutant and wtp53 carrying cells 
One of the best-characterized possibility to explain the mutp53-driven transcription of its target 
genes is the ability of mutated protein to interact with other transcription factors (TFs) and 
modulate their activities. Accordingly, we asked whether specific TFs with repressor activity 
might be involved in the mutp53-driven sIL-1Ra suppression. To this end, in silico analyses 
probing for TF consensus sequences (MatInspector) and binding peaks (ENCODE) on the sIL-1Ra 
promoter (−1680 bp) identified (i) growth factor independent 1 (GFI1),174 (ii) hairy-related 
transcription factor-1 (HRT1, HEY1),175 and (iii) v-MAF musculoaponeurotic fibrosarcoma 
oncogene family, protein F (MafF).176 To determine whether in our cells the identified TFs are 
physically recruited to the sIL-1Ra promoter, ChIP assays were performed with sh-p53 and sh-
scr HT29 cells. As shown in Fig. 9A (left panels), all analyzed TFs were found recruited to various 
extents on the sIL-1Ra regulatory regions. Of interest, only the MafF occupancy was in 
accordance with mutp53 recruitment on regions I and III (Fig. 9A, left panel). MafF belongs to 
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the small MAF subgroup of proteins that have been identified as a molecular switch capable of 
regulating gene expression in a positive or negative manner depending on their abundance.177 
Indeed, small MAFs act as heterodimers with CNC (cap’n’ collar) proteins functioning as 
transcriptional activators, whereas as homodimer they function as transcriptional repressors. 
Interestingly, the MafF promoter occupancy was significantly affected upon p53R273H 
depletion (Fig. 9A, right panel) without disturbing the MafF gene expression in either tested 
lines at the mRNA (Fig. 9B, upper panel) and protein levels (Fig. 9B, lower panel). These data 
suggest that mutp53 could act at the level of MafF recruitment on the sIL-1Ra promoter 
regulating gene expression.  
 
A        B 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. (A) MafF transcription factor is physically recruited on the sIL-1Ra promoter along with mutant p53. Occupancy of 
transcription factors with repressor activity (Gfi1, HRT1, MafF) on sIL-1Ra promoter. ChIP assays were performed with chromatins from 
sh-p53 and sh-scr HT29 cells. ChIP-enriched DNA were measured by qPCR with sets of primers specific to sIL-1Ra regulatory regions I 
and III, and outcomes quantified with respect to ‘No Ab’ set to 1.0. (B) MafF gene expression in mutp53-expressing cells. sh-scr and 
sh-p53 HT29 and MDA-MB468 cancer cells were cultured 72 h in the presence of DOX (1,0 μg/ml) before processing for RNA and 
protein extraction. Upper panel: Relative MafF mRNA levels analyzed by qPCR, normalized to β-actin housekeeping gene and 
quantified with respect to sh-scr cells set to 1.0. Lower panel: western blotting analyses performed with the indicated antibodies.  
 
We also explored whether activated wtp53 might modulate MafF gene expression and thus sIL-
1Ra production. To this aim, analyses were carried-out with Nut-3- or DMSO-treated MCF7 
cells. Activated wtp53 affects MafF gene expression, reducing both mRNA (Fig. 10A, left panel) 
and protein levels (Fig. 10A, right panel) hampering the MafF recruitment on the sIL-1Ra 
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promoter (Fig. 10B). The overall results identify MafF as a relevant player in the control of sIL-
1Ra gene expression in both mut and wtp53 carrying cell. 
A       B 
 
 
 
 
 
Figure 10. MafF gene expression in wtp53-expressing cells. (A)MCF7 cells were either treated with Nut-3 (10 μM) or DMSO (vehicle 
control). 48h later, cells were processed for RNA and protein extraction. Left panel: Relative MafF mRNA levels were analyzed by qPCR, 
normalized to β-actin housekeeping gene and quantified with respect to sh-scr cells set to 1.0. Right panel: western blotting analyses 
performed with the indicated antibodies. Densitometry was performed with the ImageJ software, values were normalized to actin and 
folds quantified with respect to controls (DMSO) set to 1.0. (B) ChIP assays were performed with chromatins isolated either from 
DMSO or Nut-3-treated MCF7 cells. 
 
 
MafF works as a common player in the regulation of sIL-1Ra gene expression by mutant and 
wtp53 proteins. 
To assess whether the mutp53 and MafF co-recruitment on the sIL-1Ra promoter might be a 
consequence of a protein–protein interaction, co-immunoprecipitation (co-IP) assays were 
performed with HT29 and MDA-MB468 cells. A 53-KDa protein recognized by an anti-p53 
antibody was detected in MafF immunoprecipitated lysates but not in the controls (Rabbit-IgG), 
demonstrating that MafF complexes to p53R273H in both cancer lines (Fig. 11A). Comparable 
results were obtained with p53R175H-carrying HEPG2 cells (Fig. 11B).  
 
 
 
 
 
 
R
e
la
ti
ve
 m
R
N
A
 le
ve
ls
MafF
DMSO Nut-3
1.2
0.8
0.4
0.0
p53 
MafF
actin
DMSO Nut-3
1 0.63 
C
N
o
-a
b
In
p
u
t
DMSO
Nut-3
M
af
F
34 
 
A       B 
 
 
 
 
 
 
 
Figure 11. MafF interacts physically with mutp53 proteins. (A) Co-IP assays performed with endogenous proteins from HT29 and 
MDA-MB468 total cell lysate. Specific anti-MafF or control Rabbit-IgG antibodies were used for IP, and anti-p53- and anti-MafF-specific 
antibodies were used for immunoblotting (IB). (B) HEPG2 cells plated in 100 mm dishes were transiently transfected with empty vector 
(pcDNA3) or encoding either p53R175H or p53R273H (4.0 µg/dish) with lipofectamine / plus reagent following manufacturer’s 
instruction. 48h later, cells were collected and processed as in (A).  
 
We next explored whether MafF might have a role in the mutp53 recruitment on the sIL-1Ra 
promoter. To this aim, ChIP assays were performed with HT29 cells upon lentiviral-based RNAi 
depletion of endogenous MafF. Efficient MafF depletion (sh-MafF) (Fig. 12, upper panel) 
significantly reduces the p53R273H recruitment to the sIL-1Ra promoter (Fig.12, lower panel). 
These results are suggesting that MafF through protein–protein interactions engages p53R273H 
on the sIL-1Ra promoter. 
 
 
 
 
 
 
 
 
 
Figure 12. MafF is responsible for mutp53recruitment 
on sIL-1Ra promoter. HT29 cells were transduced with 
either sh-MafF or sh-control (sh-con) carrying 
lentiviruses (20 MOI). 72h later, cells were collected 
and processed. (Upper panel) western blotting 
analyses performed with the indicated antibodies. 
(Lower panel) ChIP assays. Gray, dashed, square boxes 
show the p53R273H and MafF recruitment on sIL-1Ra 
promoter. 
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As the small MAFs abundance has been identified as a fine tuning molecular switch regulating 
positively or negatively gene expression,177 we enquired whether by modulating  MafF protein 
level we might perturb the sIL-1Ra gene expression. To this aim, HT29 cells have been 
transduced with increasing multiplicities of infection (MOIs) of either sh-MafF or sh-con 
carrying lentiviruses, and sIL-1Ra gene expression was followed by quantitative PCR (qPCR). As 
shown in Fig. 13A,  efficient MafF depletion (15–20 MOI) inhibits sIL-1Ra gene expression, 
whereas mild MafF reduction (30%, 10 MOI) significantly increased sIL-1Ra mRNA levels with 
respect to controls (sh-con). In agreement, mild MafF reduction increases the sIL-1Ra promoter 
activity (Fig. 13B, left panel) and the production of secreted protein (Fig. 13B, right panel). 
Similar results were achieved by using MafF-specific Stealth siRNAs (Fig. 13C).  
 
A       B 
 
 
 
 
 
 
 
 
 
C          
  
Figure 13. MafF has relevant roles in 
mutp53-driven sIL-1Ra suppression (A) 
HT29 cells were transduced with 
increasing MOIs (10, 15 and 20) of either 
sh-MafF or sh-con carrying lentivuses. 
72h later, cells were collected and 
processed to isolated total RNA. MafF 
and sIL-1Ra gene expression were 
analyzed by qPCR. Relative MafF and sIL-
1Ra mRNA levels were normalized to β-
actin housekeeping gene and quantified 
with respect to sh-con RNA set to 1.0. 
(B) HT29 cells were infected with either 
sh-MafF or sh-con carrying lentiviruses 
at MOI 10. 72h later, cells were collected and processed. (Left panel) Relative Luc activities normalized with transfection efficiency 
(βGaL) and protein quantity were quantified with respect to controls (sh-con) set to 1.0. (Right panel) Western blottings performed 
with protein lysates and CMs with the indicated antibodies. (C)HT29 cells were transfected with either Stealth siRNA specific to MafF 
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(5.0 to 80 nM) or control si-RNA (si/CT, 5.0 nM) with INTERFERin reagent following manufacturer’s instruction. Then, 36h later cells 
were collected for RNA and proteins extraction. Modulation in sIL-1Ra expression were examined by RT-PCR, whereas the MafF 
knockdown efficiency verified by IB, with anti-MafF and anti-actin specific antibodies. Densitometry was performed with ImageJ 
software, values were normalized with GAPDH or Actin, and folds quantified with respect to controls (si-CT) setted to 1.0. 
 
 
To explore whether MafF might have a role in wtp53-induced sIL-1Ra expression, we measured 
the sIL-1Ra gene expression in MCF7 cells upon MafF RNAi. At RNAi conditions mimicking  the 
MafF modulation, upon wtp53 activation, a significantly higher sIL-1Ra mRNA level was seen 
when compared to controls (sh-con) (Fig. 14). These results indicate MafF as a common player 
in the regulation of sIL-1Ra gene expression by mut and wtp53 proteins. Indeed, while activated 
wtp53 induces sIL-1Ra gene expression through MafF repression, mutp53 does not affect MafF 
gene expression but through protein–protein interaction might increase MafF abundance, 
inducing homodimers and thus sIL-1Ra suppression (Fig. 15). 
 
 
 
Figure 14. MafF has a role wtp53-induced sIL-1Ra expression. 
MCF7 cells were transduced with either sh-MafF or sh-RNA carrying 
lentiviruses at MOI 10, then 72h later cells were collected and RNA 
analyzed by RT-PCR for MafF depletion efficiency and sIL-1Ra 
expression. Densitometry was performed with ImageJ software, 
data normalized with internal control GAPDH, and quantified with 
respect to controls (sh-con) set to 1.0. Representative data of three 
independent experiments with similar results are reported.  
 
 
 
 
 
Figure 15. Cartoon model of the 
proposed p53/MafF and mutp53/MafF 
action. (Upper panel) Wtp53 reduces 
MafF RNA and protein levels, favoring 
MafF heterodimerization with other 
basic Leucine Zipper proteins (bLZ) 
carring a transactivation domain that 
activates sIL-1Ra transcription. (Lower 
panel) MafF carries mutp53 on sIL-1Ra 
promoter. Mutp53, through protein–
protein interaction, increases MafF 
abundance, induces homodimers and 
thus sIL-1Ra suppression.  
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Upon mutant p53 depletion, de-repressed sIL-1Ra blocks IL-1β response 
The sIL-1Ra specifically antagonize the IL-1 pro-inflammatory cytokine. Thus, to assess whether 
the mutp53-mediated sIL-1Ra suppression might contribute to sustain a ready-to-be-activated 
IL-1 cancer cells response, functional in vitro and in vivo assays were carried out. Because 
previous analyses (cytokine profile and reverse transcriptase–PCR) showed the absence in IL-1β 
production with both lines in unstimulated conditions (data not shown), we explored cell 
response to recombinant human (rh) IL-1β. As positive control of IL-1β blockade efficiency, 
experiments were carried out by pre-treating a subset of control cells (sh-scr) with rhsIL-1Ra 
(Kineret) at dosages revealed in mutp53-depleted HT29 and MDAMB468 CMs (0.2 and 0.5 
μg/ml, respectively). Because the IL-1β cell response can be studied in vitro by evaluating the IL-
8 gene expression,178 we found that rhIL-1β delivery rises efficiently the IL-8 mRNA in both 
tested lines (Fig.16, lanes 2 and 4 and 8 and 10), whose effects were significantly inhibited by 
mutp53 depletion (Fig.16, lanes 3 and 9) or Kineret pretreatments (Fig.16, lanes 5, 6 and 
11,12). These results indicate that in both lines mutp53 sustains the functional IL-1β signal 
cascade through the sIL-1Ra suppression.  
 
 
 
 
 
 
 
 
Figure 16. Mutant p53 sustains a prompt cell response to IL-1β by suppressing the sIL-1Ra gene expression in the studied cancer 
lines. IL-1β-induces IL8 gene expression. Engineered sh-p53 and sh-scr HT29 and MDA-MB468 cells after treatments (Material and 
methods) were collected and processed for RNA extraction. IL-8 gene expression was quantified by qPCR. Relative IL-8 mRNA levels 
were normalized with housekeeping gene β-actin and quantified with respect to controls (sh-scr+IL-1β) set to 1.0. 
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We next explored the functionality of de-repressed sIL-1Ra in non-isogenic cell system. To this 
aim, it is well established that IL-1β-induced permeability of endothelial cell monolayer 
represents an hallmark of early angiogenesis. 178,179 To explore whether de-repressed sIL-1Ra 
upon mutp53 depletion might efficiently counteract the IL-1β-induced angiogenic phenotype, 
we evaluated injuries of HUVEC cell monolayers upon co-culture with CMs generated from IL-
1β-treated sh-scr and sh-p53 HT29 cells as reported above. As shown in Fig. 17, CM from rhIL-
1β treated sh-scr cells induces significantly higher HUVEC endothelial cell death with respect to 
CM of vehicle-treated cells (Fig. 17, P = 0.014), whereas CM of either Kineret pretreated sh-scr 
(Fig.17, 0.2 μg/ml, P = 0.007 and 0.5 μg/ml, P = 0.015) or of sh-p53 (Fig.17, P = 0.018) cells 
abolish significantly the rhIL-1β induced effects. These results demonstrated that upon mutp53 
depletion de-repressed sIL-1Ra abrogated IL-1β effects with efficiency similar to the 
recombinant protein (Kineret).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 IL-1β-induced endothelial cell injury. HUVEC cell monolayers, cultured 24 h with CMs generated from sh-scr and sh-p53 
HT29 cells along with treatments (Materials and methods), were collected and endothelial cell injury assessed by trypan blue exclusion 
analyses.  
 
Previous studies have shown that IL-1β promotes proliferation of breast,180 ovarian181 and 
colon182 cancer cells in vitro. Thus we explored whether mutp53, through the sIL-1Ra 
repression, might  sustain the IL-1β-induced cell proliferation. As shown in Fig. 18, rhIL-1β 
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delivery increases 5-bromo-2’-deoxyuridine (BrdU) incorporation in both sh-scr HT29 and MDA-
MB468 cells, whose effects were efficiently rescued upon Kineret pretreatments or mutp53 
depletion (sh-p53).     
 
 
 
 
 
 
 
Figure 18. IL-1β-induced cancer cells’ proliferation. Cell proliferation of engineered sh-p53 and sh-scr HT29 (left diagram) and 
MDAMB468 (right diagram) cancer cells along treatments (Materials and methods) was assessed by BrdU incorporation assays. 
Kineret: recombinant human sIL-1Ra; rhIL-1β: recombinant human IL-1β. 
  
Mutant p53 sustains IL-1β-driven tumour malignancy through sIL-1Ra suppression 
Patients with IL-1 producing solid tumours (breast, colon, lung, head and neck and melanomas) 
have a generally worst prognosis.183,184 Likewise, preclinical studies demonstrated that local IL-1 
production influences tumour growth and metastasis either through direct proliferative effects 
or by promoting host inflammatory and angiogenic pathways.185 To explore whether mutp53, 
through the sIL-1Ra repression, might contribute to IL-1β-induced tumour malignancy, we 
investigated the growth of xenograft tumours in lipopolysaccharide (LPS)-treated mice. As LPS 
rapidly induces IL-1 production after in vivo injection,186 it constitutes a useful approach for 
studying the role of IL-1 and the antagonistic effects in different biological responses.187 
Xenograft tumours were generated either with sh-p53 or sh-scr HT29 and MDA-MB468 cells 
and LPS delivered to all mice after tumour nodule formation. To explore antagonistic efficiency 
in vivo, Kineret was delivered in peritumoural site in a subset of sh-scr tumour-bearing mice. As 
shown in Fig. 19, either mutp53 depletion (sh-p53) or Kineret delivery (sh-scr+Kineret) 
significantly inhibited tumour growth when compared with control mice (sh-scr) with both 
lines.  
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Figure 19.Mutant p53 sustains LPS-induced HT29 and MDA-MB468 xenograft tumour growth through the sIL-1Ra suppression. 
Xenograft tumours were generated with sh-scr and sh-p53 engineered HT29 and MDA-MB468 cancer cells in nude mice (CD1/SWISS). 
After tumour nodule formation, LPS (1.0 μg/mouse, intraperitoneal) and DOX (2.0 g/l, tap water) were delivered to all mice. To assess 
sIL-1Ra effects in vivo, Kineret was delivered in peritumoural regions to a subgroup of sh-scr tumour-bearing mice (sh-scr+kineret). 
Tumour growth was followed by caliper measurements twice a week.  
 
We next explored the IL-8 gene expression in excised tumours to evaluate IL-1 effects in vivo. 
Significantly higher IL-8 mRNA was found upon LPS delivery with respect to vehicle-treated 
mice (Fig. 20, HT29: lane 1 vs 2; MDA-MB468: lane 1 vs 2). By contrast, either Kineret delivery 
or mutp53 depletion abolished LPS-induced IL-8 mRNA (Fig. 20, HT29: lane 2 vs lanes 3, 4 and 5, 
6; MDA-MB468: lane 2 vs lanes 3, 4 and 5–7). The overall results demonstrate that de-
repressed sIL-1Ra, upon mutp53 depletion, inhibits the IL-1β cancer cell response in vitro and in 
vivo.  
 
 
 
A
p<0.05
p<0.05
p<0.01
0 10 20 30
Tu
m
o
r 
V
o
lu
m
e
 (
cm
3
)
Time (days)
sh-scr
sh-scr + Kineret
sh-p53
HT29
MDA-MB468
0 2 4 6 8
Tu
m
o
r 
V
o
lu
m
e
 (
cm
3
)
Time (Weeks)
0.3
0.2
0.1
0.0
0.4
0.5
0.6
0.7
0.2
0.0
0.4
0.6
0.8
1.0
41 
 
 
Figure 20. IL-8 levels in the tumours. Xenograft tumours generated as in Fig.19 were excised, and RNAs were isolated. qPCRs were 
performed to analyze the human IL-8 gene expression along with treatments in vivo. Relative IL-8 mRNA levels were normalized with 
housekeeping gene human β-actin and quantified with respect to control tumours (sh-scr) set to 1.0.  
 
To further support our studies, we evaluated IL-1Ra expression in primary tumours public gene 
expression data repositories (Oncomine). Analyses of data sets from specimens of primary 
tumours with respect to normal tissues revealed a significantly lower IL-1Ra and consistently 
higher IL-1β mRNA in the colon (Fig. 21A) and breast (Fig. 21B). Noteworthy, analyses based on 
p53 mutational status revealed a significantly lower IL-1Ra in colon tumours carrying p53 
mutations in comparison to those with wtp53 (Fig. 21C). Taken together, our studies provide 
the first evidence of a molecular and functional link between mutp53 and sIL-1Ra and provide 
new insights on the role of p53 mutants in oncogenic GOF activity in human cancer. 
All the data previously described have been successfully published on Oncogene journal 
(Ubertini V. et al., 2014).188 
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Figure 21. Public gene expression data repositories (Oncomine) of mammary and colon primary tumours. The box plots revealed the 
relative mRNA levels of sIL-1Ra and IL-1β in primary tumours of colon (a) and breast (b) with respect to normal tissue. (c) The box plots 
indicates the IL-1Ra mRNA levels in primary colon tumours carrying either wild-type or mutant p53. 
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Results-part 2 
 
Xenograft models are generated by implantation of human cancer cells in immunodeficient 
mice to avoid human cells rejection. This kind of model could not be  completely suitable to 
study the modulation of the whole tumour microenvironment, because of the lack of a part of 
the immune response which could be involved in tumour progression as well as in tumour 
regression. Indeed, CD1-Nude mice  lack  thymus, and thus cannot generate mature T 
lymphocytes. Thus, to better understand the role of mutp53 in TME crosstalk we shifted our 
studies to more physiological experimental models as genetically engineered knock-in mice 
carrying p53R172H mutation, an ortholog of the human “hot spot” mutant p53R175H. Since R175H 
is the second most common site of missense mutation in human breast cancer, tumours have 
been induced chemically. The selected mutp53 knock-in mice because totally 
immunocompetent would allow to study the tumour microenvironment in its entirety 
Generation of mutant p53 mice sensible to chemical induction of mammary tumours. 
Several data in literature suggest FVB mice background as  the most suitable model to perform 
studies of tumour chemical induction (e.g. Dimethylbenz(a)anthracene).167 A colony of 
genetically engineered mice (GEM) carrying p53R172H mutation in C57BL/6 background are 
available to the animal facility at Regina Elena National Cancer Institute. To obtain GEM with 
FVB background, C57BL/6 p53+/R172H  were backcrossed with FVB+/+ mice for 3 generations (N3) 
(Fig. 22), obtaining mice with a 87,5%  FVB and 12,5% with C57BL/6 background. 
A B 
 
  
 
 
 
 
 
Figure22.(A) Schematic representation of backcrossing. (B) Congenic strain production strategy. 
Generation Recipient genome 
N1 50.00% 
N2 75.00% 
N3 87.50% 
N4 93.75% 
N5 96.88% 
N6 98.44% 
N7 99.22% 
N8 99.61% 
N9 99.81% 
N10 99.90% 
C57BL/6 FVB 
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To obtain p53+/R172H, p53R172H/R172H  and p53+/+ female mice (Fig. 23),  we crossed heterozygous 
FVB p53+/R172H N3 brothers and sisters. Then, F1 female mice were used for chemical mammary 
tumour induction, as described below. 
 
 
    
 
 
 
 
 
 
Figure 23. (Upper panel)Generation of p53 +/R172H (HZ), p53 R172H/R172H(HO)  and p53+/+(WT) mice. (Lower panel) PCR 
genotyping.   
   
Mutant p53 induces less differentiated tumours with respect to the wild type. 
Mammary tumours were induced with well-established experimental protocol: 
medroxyprogesterone acetate (MPA) plus Dimethylbenz(a)anthracene (DMBA).168 The 6 weeks-
old female p53+/R172H, p53R172H/R172H  and p53+/+ mice have been subcutaneously implanted with 
a MPA pellet and DMBA delivered at weeks 9,10 and 11,12. 168 After treatments, animals were 
monitored twice a week for tumour appearance. Results showed that mutp53 impacts 
significantly on tumour onset in a gene dosage dependent manner (Table 1). Indeed a lag time 
of 13 days was required in homozygous mutp53R172H (p53R172H/R172H) mice with respect to 64 
and 99 days in heterozygous p53+/R172H,  and  wtp53 p53+/+ mice respectively. 
 
Mice p53  R172H/R172H p53 R172H/+ p53 +/+ 
Post-treatment time 
to tumourigenesis 
(days) 
13 ± 11 64 ± 15 99 ± 28 
Table 1. Post-treatments time needed to tumourigenesis. 
N3 Brother x Sister
F1 HZ HO WT
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At established end-point (tumour volume 1,0 cm3), animals were euthanized and tumours 
excised. The Hematoxylin and Eosin (H&E) stain on formalin fixed tumours revealed that 
mutp53 bearing tumours (p53R172H/R172H) showed a less differentiated phenotype when 
compared to wtp53 carrying tumours (p53+/+ )(Fig.24). Noteworthy, mutp53 heterozygous 
tumours revealed an intermediate phenotype further supporting the mutp53 dose dependent 
effects. Indeed, higher p53 stain was found in  p53R172H/R172H with respect to p53+/R172H 
heterozygous tumours, whereas p53+/+  were completely negative (Fig. 24). These data might 
suggest an important role of mutp53 in the structural organization of tumours. 
 
Figure24.(Upper panel) Hematoxylin and Eosin staining of chemically induced breast tumours .(Lower panel) IHC analysis of p53.
 
Mutant p53 might play relevant roles in TAMs recruitment. 
To explore whether mutp53 might have a role in the recruitment of specific tumour infiltrating 
cells, immunohistochemistry (IHC) studies were performed. Results show that mutp53 
occurrence (p53R172H/R172H, p53+/R172H) correlates significantly with higher macrophages 
infiltration with respect to the wild type (p53+/+) tumours (Fig. 25). Differently non-significant 
difference were observed when IHC stains were performed to analyze neutrophils tumour 
infiltration (Fig. 25). Results are suggesting that mutp53 might modulate the tumour 
microenvironment by increasing the production of cytokines  responsible for the specific 
macrophages recruitment. To confirm this hypothesis,  semi-quantitative RT-PCR were 
performed to analyze the expression of specific cytokines involved in macrophages 
p53R172H/R172H p53+/R172H p53+/+
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chemoattraction. Primary data show higher MCP1 mRNA levels in p53R172H/R172H tumours 
whereas intermediate and low levels were found in p53+/R172H  and p53+/+  tumours respectively 
(Fig.26). 
 
 
Figure25. IHC analysis of F4/80+ cells (macrophages) and Ly6G+ cells (neutrophils). 
 
 
 
 
 
 
Figure26. Total RNAs were isolated from chemically induced tumours  and analyzed by PCR. 
MCP-1 levels were normalized by the housekeeping gene GAPDH. Relative mRNA levels 
were quantified with respect to WT  RNA set to 1.0. 
 
 
These data are supporting the hypothesis that  mutp53  is involved in the enrollment of 
macrophages into the tumour milieu, which are also the principal producers of IL-1β cytokine 
known to have an important role in tumour initiation and progression. 
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Production of a mutant p53 cancer cell line used to generate an immunocompetent model of 
breast cancer 
Studies of tumour induction in GEM mice, albeit physiologically relevant, are complex and time 
consuming. Moreover, suitable models to assess in vitro and in vivo the mutp53-TME crosstalk 
are missing. Thus, the identification of murine cell lines harboring p53 mutations enable to 
generate syngeneic orthotopic breast tumours will be preferable. To this aim, studies were 
performed in isolating and characterizing a mutp53 cancer line from p53R172H/R172H chemically 
induced breast tumour. Isolated cell line, named 44-1, grows well in vitro and in vivo (Fig.27) 
after implantation (2,0x10^6 cells/mouse) into the mammary fat pad of syngeneic FVB female 
mice. Moreover, 44-1 cells induce tumours with multicellular organization and p53 stain very 
similar to the chemically induced tumours in p53R172H/R172H mice (Fig.28), confirming the 
relevance of mutp53 in the structural organization of tumours.  
 
 
 
 
 
 
Figure27.Tumour growth of 44-1 cell line implanted into the fat pad 
mammary gland of FVB immunocompetent mice.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure28.(Upper panel) Hematoxylin 
and Eosin staining of chemically 
induced  p53 R172H/R172H and 44-1 
derived breast tumours. (Lower 
panel) IHC analysis of p53. 
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Overall, the isolated 44-1 line allows a novel experimental model to study mutp53 function in 
vitro and in vivo. Indeed, 44-1 cells might be easily engineered to conditionally silence 
endogenous mutp53 allowing us to link the mutp53 activity to the recruitment of macrophages 
or other cells of the immune system as well as  to the production of specific 
cytokines/chemokines that might contribute to tumour malignancy. Moreover, this model will 
be helpful to analyze the role of Kineret in the treatment of mutp53 tumours by using a more 
physiological system that contains all the cells potentially needed to tumour progression. 
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Chapter 5 
Discussion 
 
 
Tumour growth is the result of a complex interaction between cells that progressively 
acquire molecular alterations and a transformed phenotype, and the surrounding host cells 
that may inhibit or promote cancer cell growth and tumour progression. 
Chronic inflammation has been recognized as one of the main cause of cancer onset and 
progression. Many pro-inflammatory cytokines induce chronic inflammation and among them 
IL-1β plays one of the most important roles, being involved in all the steps of tumour 
malignancy. Indeed, human cancers producing high levels of IL-1β are frequently associated 
with bad prognosis.155,184,185  p53 missense point mutations are reported to add novel oncogenic 
functions through which altered proteins actively contribute in tumour malignancy. Since the 
majority of human cancers carry p53 mutations, the consequences of its direct activity on 
cancer cell behaviour have been studied thoroughly. In the last few years, increasing efforts 
have been dedicated to the correlation of mutp53 occurrence with specific changes in the TME 
with the purpose to understand whether mutp53 might indirectly sustain cancer progression, 
by generating a pro-tumourigenic microenvironment that in turn sustains cancer growth and 
spread. However, this novel field has not yet been examined in depth. Our studies shed new 
lights on the putative ability of mutp53 to modulate the TME. Indeed we found that mutp53, 
through the sIL-1Ra suppression, contributes to maintain a prompt IL-1β cancer cell response 
sustaining a pro-inflammatory TME. Accordingly, latest molecular studies reported mutp53 to 
sustain cancer progression by increasing nuclear factor κB (NFκB) activation in the context of 
chronic inflammation both in vitro and in vivo.82,162 Notably, IL-1β induces the expression of 
canonical IL-1 inflammatory target genes through the activation of NFκB signaling pathway. This 
allows us to speculate that the mutp53-driven sIL-1Ra suppression could constitute a novel 
mechanism through which mutp53 might sustain the IL-1β-induced NFκB activation.  Our 
results provide important insights into mutp53 GOFs and might aid in the development of new 
prognostic tools and therapeutic strategies against tumours carrying p53 mutations. Overall 
results suggest that the targeting of IL-1 activity might constitute a novel valid therapeutic 
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intervention, in combination with existing clinical treatments, against mutp53 carrying 
tumours. The recombinant human sIL-1Ra protein (Kineret) is actually used for treating 
rheumatoid arthritis.189 Hence, it might turn out as effective in other diseases, likewise cancer, 
as assessed by preclinical studies showing reduced cell proliferation, tumour development and 
angiogenesis in mice upon recombinant sIL-1Ra (Kineret) delivery.190,191  
The identification of a suitable immunocompetent mouse model to better investigate 
the link between mutp53 and the TME will allow to contribute for a complete understanding of 
the mutp53 roles in cancer. Our preliminary results with chemically induced tumours in mutp53 
GEM are promising since are suggesting a more complex role of mutp53 in building an 
environment that supports cancer progression. Indeed, we found that the mutp53 occurrence 
seems to be correlated with a more undifferentiated tumour phenotype and involved in the 
recruitment into the tumour milieu of specific host-cells as macrophages. TAMs, characterized 
by an M2-like phenotype, have been described as tumour-promoter cells, helping cancer 
progression by producing several types of molecules. Notably, macrophages are one of the 
principal producers of IL-1β. Most solid tumours recruit macrophages through the production 
of specific cytokines and chemokines,113-115 and preliminary results  revealed  higher MCP-
1/CCL2 production in mutp53 tumours with respect to the wild type, highlighting the 
importance of possible mutp53 roles in TAMs recruitment. The orthotropic implantation of 44-1 
cells into FVB mice generated tumours with a multicellular organization comparable to 
chemically induced p53R172H tumours, strengthening the hypothesis that mutp53 plays a role in 
tumour's level of differentiation. 
The employment of the syngeneic orthotopic breast tumour model to study mutp53/TME 
crosstalk is feasible , less expensive and also more reliable than the use of GEM, and allows to 
overcome difficulties in results interpretation due to the presence of a mutant protein in all the 
host cells. The use of  44-1 breast cancer model will allow the discrimination of mutp53 derived 
effects on TME from effects not directly correlated with the presence of a mutated protein. 
This model, moreover, will be useful to study the Kineret effects in immunocompetent mice 
and to identify novel potential therapeutic strategies. 
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